Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selincro (nalmefene) as-needed in alcohol-dependent patients with liver impairment
2014-000413-31Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nalmefene in alcohol dependence and alcoholic liver disease (ALD), sponsored by Lundbeck. Primary endpoint: Therapeutic effect on reduction of alcohol consumption. Started Apr 2014; status: completed.
02
Drugs
nalmefene
03
Conditions
alcohol dependencealcoholic liver disease (ALD)
Beyond the preview
Go deeper on 2014-000413-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000413-31.